BCDA BioCardia Inc
Price (delayed)
$2.27
Market cap
$10.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.9
Enterprise value
$9.2M
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's
Highlights
The EPS has soared by 65% YoY and by 30% from the previous quarter
The debt has declined by 28% year-on-year and by 9% since the previous quarter
The equity has surged by 152% year-on-year but it has dropped by 70% since the previous quarter
BioCardia's net income has increased by 31% YoY but it has decreased by 2.9% from the previous quarter
BioCardia's gross profit has plunged by 88% YoY and by 18% from the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of BCDA
Market
Valuations
Earnings
Shares outstanding
4.68M
Market cap
$10.62M
Enterprise value
$9.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
12.43
Price to sales (P/S)
107.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
158.68
Revenue
$58,000
Gross profit
$58,000
Operating income
-$8M
Net income
-$7.95M
EBIT
-$7.95M
EBITDA
-$7.52M
Free cash flow
-$8.03M
Per share
Balance sheet
Liquidity
EPS
-$2.9
EPS diluted
-$2.9
Free cash flow per share
-$2.93
Book value per share
$0.18
Revenue per share
$0.02
TBVPS
$1.36
Total assets
$3.72M
Total liabilities
$2.89M
Debt
$951,000
Equity
$837,000
Working capital
$301,000
Debt to equity
1.14
Current ratio
1.13
Quick ratio
1.02
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-12,958.6%
Gross margin
100%
Net margin
-13,700%
Operating margin
-13,794.8%
Return on assets
-204.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-566.4%
Return on sales
-13,700%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCDA stock price
How has the BioCardia stock price performed over time
Intraday
6.07%
1 week
-10.98%
1 month
12.94%
1 year
-62.17%
YTD
4.13%
QTD
-10.63%
Financial performance
How have BioCardia's revenue and profit performed over time
Revenue
$58,000
Gross profit
$58,000
Operating income
-$8M
Net income
-$7.95M
Gross margin
100%
Net margin
-13,700%
BioCardia's gross profit has plunged by 88% YoY and by 18% from the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 18% from the previous quarter
BioCardia's operating income has increased by 31% YoY but it has decreased by 3.1% from the previous quarter
BioCardia's net income has increased by 31% YoY but it has decreased by 2.9% from the previous quarter
Growth
What is BioCardia's growth rate over time
Valuation
What is BioCardia stock price valuation
P/E
N/A
P/B
12.43
P/S
107.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
158.68
The EPS has soared by 65% YoY and by 30% from the previous quarter
The equity has surged by 152% year-on-year but it has dropped by 70% since the previous quarter
BioCardia's revenue has plunged by 88% YoY and by 18% from the previous quarter
BCDA's P/S is 54% above its last 4 quarters average of 65.6 and 4.5% above its 5-year quarterly average of 96.9
Efficiency
How efficient is BioCardia business performance
The ROS has contracted by 26% from the previous quarter
The ROA has grown by 11% YoY
Dividends
What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCDA.
Financial health
How did BioCardia financials performed over time
BCDA's total assets is 29% higher than its total liabilities
BCDA's current ratio has soared by 183% YoY but it is down by 37% QoQ
BCDA's quick ratio is down by 41% from the previous quarter
The debt is 14% greater than the equity
BioCardia's debt to equity has soared by 200% from the previous quarter
The equity has surged by 152% year-on-year but it has dropped by 70% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.